A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.
- Football-loving states slow to enact youth concussion laws
- Lab results don’t explain ‘obesity paradox,’ but bias may
- New device offers faster way to detect antibiotic-resistant bacteria
- Flashy lizards are more attractive to mates and to predators
- Octapharma USA presents bleeding disorders research at virtual ASH annual meeting